Efficacy of Topical Cetirizine 1% in Treatment of Androgenic Alopecia: Clinical and Dermoscopic Evaluation

July 2023 in “ Research Square (Research Square) ”

Sara Ahmed Galal, Wafaa Afify Mahmoud, Noha Ahmed

cetirizine androgenic alopecia androgenetic alopecia terminal hairs vellus hair hair diameter diversity Zyrtec AGA

Studysummary In this study, the application of topical cetirizine 1% once daily for four months in Egyptian male patients with androgenetic alopecia led to a significant increase in terminal hairs and improved hair diversity, with promising safety and efficacy outcomes.

Our plain-language summary. Not medical advice or a treatment recommendation. Consult a qualified healthcare professional before changing treatment. Full disclaimer

The study "Efficacy of Topical Cetirizine 1% in Treatment of Androgenic Alopecia: Clinical and Dermoscopic Evaluation" conducted on 50 Egyptian male patients with androgenetic alopecia (AGA) found that topical cetirizine 1% showed promising results in treating AGA. After 4 months of daily treatment, there was a significant increase in the number of terminal hairs, a decrease in the number of vellus hair, and a reduction in hair diameter diversity. The study also noted mild to good photographic improvement in patients. The treatment demonstrated an excellent safety profile, suggesting it could be a viable option for patients in the future.

View this study on researchsquare.com →

Community mentions of this study Join

1 results

Efficacy of Topical Cetirizine 1% in Treatment of Androgenic Alopecia: Clinical and Dermoscopic Evaluation

January 2025, 2 posts

Farbod_Sajadi

tressless.com Efficacy of Topical Cetirizine 1% in Treatment of Andr...

Research cited in this study

11 / 11 results

research Efficacy of Cetirizine 1% Versus Minoxidil 5% Topical Solution in the Treatment of Male Alopecia: A Randomized, Single-Blind Controlled Study

7 citations , April 2021 in “Journal of Pharmacy and Pharmaceutical Sciences”

This study found that while both cetirizine 1% and minoxidil 5% increased hair density in men with androgenetic alopecia, minoxidil showed a significantly higher improvement, and both treatments lost effectiveness after 8 weeks without use; cetirizine was well-tolerated with no significant adverse reactions.

A Hypothetical Pathogenesis Model for Androgenic Alopecia: Clarifying the Dihydrotestosterone Paradox and Rate-Limiting Recovery Factors

research A Hypothetical Pathogenesis Model for Androgenic Alopecia: Clarifying the Dihydrotestosterone Paradox and Rate-Limiting Recovery Factors

30 citations , December 2017 in “Medical Hypotheses”

This review evaluates dihydrotestosterone's role in androgenic alopecia and proposes a model suggesting that chronic scalp tension and inflammation contribute to hair follicle miniaturization, identifying fibrosis, calcification, and tension as treatment targets.

research Prostanoids and Hair Follicles: Implications for Therapy of Hair Disorders

16 citations , November 2017 in “Acta dermato-venereologica”

This review examines how different prostanoids and their receptors affect hair growth but provides no new clinical results; it highlights potential implications for treating hair disorders.

research A Preliminary Study on Topical Cetirizine in the Therapeutic Management of Androgenetic Alopecia

21 citations , June 2017 in “Journal of Dermatological Treatment”

This study found that topical cetirizine 1% significantly improved hair density and diameter in patients with androgenetic alopecia, with patients tolerating the treatment well.

research Enhancing Hair Growth in Male Androgenetic Alopecia by a Combination of Fractional CO2 Laser Therapy and Hair Growth Factors

26 citations , May 2017 in “Lasers in Medical Science”

This study found that combining ablative fractional CO₂ laser therapy with hair growth factors significantly increased hair density in men with androgenetic alopecia compared to using growth factors alone.

research Addressing Androgenetic Alopecia: A Complex Disorder with a Multilateral Treatment Strategy

1 citations , February 2017 in “MOJ bioequivalence & bioavailability”

This review discusses recent advancements in understanding the pathophysiology of androgenetic alopecia and highlights the potential for multilateral topical therapies to improve treatment efficacy with fewer side effects; it reports no new clinical results.

research Topical Cetirizine and Oral Vitamin D: A Valid Treatment for Hypotrichosis Caused by Ectodermal Dysplasia

4 citations , August 2016 in “JEADV. Journal of the European Academy of Dermatology and Venereology/Journal of the European Academy of Dermatology and Venereology”

This case report observed that after 6 months of treatment with topical cetirizine and oral vitamin D, hair density and quality improved in three girls with congenital hypotrichosis due to ectodermal dysplasia.

research Does Prostaglandin D2 Hold the Cure to Male Pattern Baldness?

57 citations , February 2014 in “Experimental Dermatology”

This review discusses the role of Prostaglandin D2 and its synthase in androgenetic alopecia but reports no new clinical findings, suggesting pathways for future therapeutic development.

research Prostaglandin D2 Inhibits Hair Growth and Is Elevated in Bald Scalp of Men with Androgenetic Alopecia

205 citations , March 2012 in “Science Translational Medicine”

PGD2 stops hair growth and is higher in bald men with AGA.

research Role of Genetics and Sex Steroid Hormones in Male Androgenetic Alopecia and Female Pattern Hair Loss: An Update

87 citations , March 2011 in “Australasian Journal of Dermatology”

This review explores the current understanding of genetic and hormonal influences on male androgenetic alopecia and female pattern hair loss, providing guidance for clinicians but reports no new results.

research Hair Loss, Insulin Resistance, and Heredity in Middle-Aged Women: A Population-Based Study

49 citations , June 2003 in “European journal of cardiovascular prevention & rehabilitation”

In this study, female androgenic alopecia (grade II or III on Ludwig's scale) was found to be common among Finnish women aged 63, and several markers of insulin resistance, along with paternal history of alopecia, were associated with an increased risk.